TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
Date Issued
2017-10-04
Date Acceptance
2017-09-11
Citation
Frontiers in Immunology, 2017, 8
ISSN
1664-3224
Publisher
Frontiers Media
Journal / Book Title
Frontiers in Immunology
Volume
8
Copyright Statement
© 2017 Kaufmann, Dockrell, Drager, Ho, McShane, Neyrolles, Ottenhoff, Patel, Roordink, Spertini, Stenger, Thole, Verreck, Williams and TBVAC2020 Consortium. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
License URL
Subjects
Science & Technology
Life Sciences & Biomedicine
Immunology
tuberculosis
bacille Calmette-Guerin
vaccination
biomarker
clinical trial
portfolio management
discovery
HEPARIN-BINDING HEMAGGLUTININ
BOVIS BCG-VACCINATION
CD4 T-CELLS
MYCOBACTERIUM-TUBERCULOSIS
IMMUNE-RESPONSES
ACTIVE TUBERCULOSIS
PROTECTIVE IMMUNITY
DOUBLE-BLIND
PHASE-II
INFECTION
Publication Status
Published
Article Number
1203